PDCD1 and lung carcinoma: Since the introduction of immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1) and its ligand (PD‐L1) pathway, the treatment landscape for patients with lung cancer has dramatically changed.